IOP lowering effect of topical trans-resveratrol involves adenosine receptors and TGF-β2 signaling pathways

Eur J Pharmacol. 2018 Nov 5:838:1-10. doi: 10.1016/j.ejphar.2018.08.035. Epub 2018 Aug 29.

Abstract

Trans-resveratrol was earlier shown to lower intraocular pressure (IOP) in rats; however, its mechanisms of action remain unclear. It has been shown to modulate adenosine receptor (AR) and TGF-β2 signaling, both of which play a role in regulating IOP. Hence, we investigated effects of trans-resveratrol on AR and TGF-β2 signaling. Steroid-induced ocular hypertensive (SIOH) rats were pretreated with A1AR, phospholipase C (PLC) and ERK1/2 inhibitors and were subsequently treated with single drop of trans-resveratrol. Metalloproteinases (MMP)-2 and -9 were measured in aqueous humor (AH). In another set of experiments, effect of trans-resveratrol on AH level of tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) was determined after single and multiple drop administration in SIOH rats. Effect of trans-resveratrol on ARs expression, PLC and pERK1/2 activation and MMPs, tPA and uPA secretion was determined using human trabecular meshwork cells (HTMC). Further, effect of trans-resveratrol on TGF-β2 receptors, SMAD signaling molecules and uPA and tPA expression by HTMC was determined in the presence and absence of TGF-β2. Pretreatment with A1AR, PLC and ERK1/2 inhibitors antagonized the IOP lowering effect of trans-resveratrol and caused significant reduction in the AH level of MMP-2 in SIOH rats. Trans-resveratrol increased A1AR and A2AAR expression, cellular PLC, pERK1/2 levels and MMP-2, tPA and uPA secretion by HTMC. Additionally, it produced TGFβRI downregulation and SMAD 7 upregulation. In conclusion, IOP lowering effect of trans-resveratrol involves upregulation of A1AR expression, PLC and ERK1/2 activation and increased MMP-2 secretion. It downregulates TGFβRI and upregulates SMAD7 hence, inhibits TGF-β2 signaling.

Keywords: Adenosine receptors; Intraocular pressure; Steroid-induced; Trabecular meshwork; Transforming growth factor- β2; trans-resveratrol.

MeSH terms

  • Adenosine A1 Receptor Antagonists / pharmacology
  • Administration, Ophthalmic
  • Animals
  • Cells, Cultured
  • Dexamethasone / pharmacology
  • Disease Models, Animal
  • Down-Regulation / drug effects
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Male
  • Ocular Hypertension / chemically induced
  • Ocular Hypertension / drug therapy*
  • Primary Cell Culture
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P1 / metabolism
  • Resveratrol / pharmacology*
  • Resveratrol / therapeutic use
  • Signal Transduction / drug effects*
  • Trabecular Meshwork / cytology
  • Trabecular Meshwork / drug effects
  • Transforming Growth Factor beta2 / metabolism
  • Treatment Outcome
  • Type C Phospholipases / antagonists & inhibitors
  • Type C Phospholipases / metabolism
  • Up-Regulation / drug effects

Substances

  • Adenosine A1 Receptor Antagonists
  • Receptors, Purinergic P1
  • Tgfb2 protein, rat
  • Transforming Growth Factor beta2
  • Dexamethasone
  • Type C Phospholipases
  • Resveratrol